Patient with brain metastases of malignant melanoma a long‑term surviving with BRAF and MEK inhibitor in combination therapy

03/2018

MUDr. Ilona Procházková

Dermatovenerologická klinika 1. LF UK a VFN, Praha

 

SUMMARY

In recent years, there has been a significant shift in the treatment of generalized malignant melanoma due to the introduction of targeted BRAF and MEK inhibitors in patients with BRAF mutation in tumor cells and modern immunotherapy using antibodies against immune response checkpoints. The results of clinical trials have confirmed a significantly higher response rate and an increase in overall survival in patients treated with both types of medication.

 

KEY WORDS

melanoma, immunotherapy, BRAF inhibitor, MEK inhibitor

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM